Company intelligence / Profile preview
Pulmovant
Waltham, Massachusetts, United Statespulmovant.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pulmovant’s lead asset, mosliciguat, is an inhaled small molecule sGC activator being developed as a once-daily treatment for pulmonary hypertension associated with interstitial lung disease. Phase 1 data showed up to a 38% reduction in pulmonary vascular resistance—one of the highest reductions seen in PH trials to date. The drug is currently being evaluated in a global Phase 2 trial ("PHocus") and has shown promising safety and efficacy signals so far
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculeInhaled drug delivery therapySoluble guanylate cyclase activator (sGC activator)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bayer AG — exclusive worldwide license for mosliciguat
Beyond the preview
Go deeper on Pulmovant.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pulmovant.